Kornimate/medical-research-clean huggingface dataset:
understand fog in pd: behavioral physiology and clinical application

Conditions: Parkinson Disease; Freezing of Gait

Summary: the overall goals of this proposed study are to investigate the behavioral and neurophysiological mechanisms of patients with parkinson's disease (pd) experiencing freezing of gait (fog). more specifically, we aim to determine the behavioral changes in context-dependency and changes in corticomotor excitability associated with fog.

background: freezing of gait (fog) is a debilitating symptom for patients with parkinson's disease (pd). fog not only impairs walking but also significantly increase fall risks and decrease quality of life for patients with pd. despite the critical consequences, the mechanisms associated with this phenomenon are not well understood. clinically, fog often occurs when individuals with pd are approaching a narrow pathway or crossing a busy street. this observation leads to the hypothesis that fog is associated with context-dependent motor performance, a phenomenon that an individual demonstrate poorer performance if the learned motor task is carried out in an unfamiliar context. whether the occurrence of freezing episodes is a result of context-dependency has not been systematically investigated. moreover, the changes in corticomotor excitability associated with fog have not been well-established. objectives: the objectives of this proposal are to understand the behavioral and neurophysiological mechanisms of fog. the specific aim is to examine the behavioral changes in context-dependency and changes in corticomotor excitability associated with fog. methods: a total of 70 participants, including pd patients with fog, pd patients without fog, and age-matched non-disabled adults, will be recruited. the participants will undergo behavioral and neurophysiological examinations. behavioral evaluations will include context-dependent motor performance, fog, disease severity, and walking and balance functions. transcranial magnetic stimulation and electroencephalogram will be used to measure corticomotor excitability of the participants. analysis of variance (anova) and regression analysis will be performed to compare and determine the relationship between fog, behavioral outcomes, and corticomotor excitability. statistical significance level is set at p \< 0.05.

Eligibility criteria:
inclusion criteria: * individuals with parkinson's disease * healthy control subjects exclusion criteria: * unable to follow the instructions * have other neurological diseases other than pd * have pacemaker implanted in their body * have a history of seizure * have a family history of epilepsy

Keywords: parkinson's disease freezing of gait context-dependency transcranial magnetic stimulation visual cues
longitudinal observational biomarker study

Conditions: Depression; Dementia; Mild Cognitive Impairment

Summary: the purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.

the purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function. the study will also test if changes in brain structure and function are associated with decreases in memory. in this study, investigators will conduct a series of assessments/tests, mainly brain imaging and assessments of participant's memory and attention, to better understand how depression is linked to memory and thinking in older persons. investigators hope that their study will help the scientific community to understand why some people with depressive symptoms that are resistant to treatment in late-life experience declines in their memory and attention and whether effective treatment of such depression reduces that risk. finally, investigators hope that this study will eventually lead to the development of better treatment options.

Eligibility criteria:
inclusion criteria: * men and women aged 60 and older * current major depressive disorder (mdd) * failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length * patient health questionnaire-9 (phq-9) score of 10 or higher exclusion criteria: * dementia * lifetime diagnosis of bipolar i or ii disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms. * high risk for suicide and unable to be managed safely in the clinical trial * non-correctable, clinically significant sensory impairment interfering with participation * unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management. * moderate to severe substance or alcohol use disorder * seizure disorder. * parkinson's disease * individuals with any contraindications to mri
paliperidone extended-release (er) versus risperidone for neurocognitive function in patients with schizophrenia

Conditions: Schizophrenia

Summary: primary objective: to examine whether the switch to paliperidone er from risperidone improves cognitive function in stabilized patients with schizophrenia. secondary objectives: to compare the general clinical outcomes (efficacy and safety) after switching to paliperidone er from risperidone

this is a 12-week, randomized, parallel-group, open labeled, flexible-dose study. the patients will be randomized to the risperidone-continuation group in which they continue to receive risperidone, or to the paliperidone-switch group in which they are switched from risperidone to paliperidone. in the paliperidone-switch group, risperidone will be tapered off during the first 4 weeks of the study, while paliperidone is titrated simultaneously. the doses of both drugs will be adjusted according to the clinical judgment of each research psychiatrist, within 6 mg/day of risperidone and 12 mg/day of paliperidone.

Eligibility criteria:
inclusion criteria: * patients diagnosed as schizophrenia by dsm-iv-tr criteria both in inpatients * patients who are symptomatically stable, as judged by the treating psychiatrist, and receive a stable dose of risperidone for a minimum of 2 weeks before enrollment. * patients with ability to complete various questionnaires. * patients and/or their legal guardians/representatives who sufficiently understand the objective of the study and sign informed consent form exclusion criteria: * active psychotic symptoms, including severe behavioral disturbance * relevant history of or current presence of any significant or unstable medical disease * a woman who is pregnant, breast-feeding or planning to become pregnant during the study period * patients with the history of serious allergy or multiple adverse drug reactions * patients with the history of taking paliperidone er within 60 days * patients with history of taking clozapine within 60 days * patients who require the treatment of other medications influencing cns, except permitted concomitant drugs in advance
the effect of manual lymphatic drainage on acute and post-acute ankle sprain in athletes

Conditions: Ankle Sprains

Summary: manual lymphatic drainage techniques (mldts) are special techniques in manual therapy used in rehabilitation for treatment of physical dysfunctions and pathologies. such practices could be done by medical team or clinicians. theories on mldts address functions like stimulating the lymphatic system by increasing lymph circulation, facilitating the removal of waste products from body tissues, reducing edema, and decreasing the responses of sympathetic nervous system while increasing the parasympathetic nervous tone leading to a relaxed body state.

this study will examine the effect of manual lymphatic drainage on pain intensity, ankle swelling, range of motion, static and dynamic functional stability in acute and post-acute ankle sprain in athletes. edema treatment includes a variety of techniques; elevation, compression, electrical stimulation, ultrasound, and massage are a few of them. profound clinical check is required to determine the kind of edema management. however, the effect of these techniques on the lymphatic system and the edema itself is questionable. manual lymphatic drainage mechanism, although still under investigation, is also a valid treatment management that does not cause inflammation, reduces the absorption of waste products and excess fluid and still urges the lymphatic system to work better.

Eligibility criteria:
inclusion criteria: 1. . basketball athletes patients diagnosed as acute and post-acute ankle sprain. 2. patients within 18 and 30 years old. 3. patients with grade i, ii ankle inversion sprain. 4. all participants complains of pain and moderate swelling in the ankle. exclusion criteria: 1. previous ankle surgery. 2. serious pathology. 3. history of fractures in the ankle joint. 4. vascular disorders. 5. grade iii ankle sprain.

Keywords: ankle sprain athletes manual lymphatic drainage
multidimensional examination of patients with colorectal and anal cancer

Conditions: Colorectal Cancer; Anal Cancer; Physical Inactivity; Fecal Incontinence; Quality of Life

Summary: the aim of our cross-sectional research is to assess changes in physical activity, functional capacity, and health status in individuals with colorectal and anal carcinoma using subjective measurement tools, with particular focus on those suffering from incontinence, through a cross-sectional study. additionally, the research involves the hungarian adaptation and validation of the quality of life questionnaire for colorectal cancer (eortc qlq-cr29), quality of life questionnaire for anal cancer (eortc qlq-an27), and fecal incontinence severity index (fisi)" questionnaires.

colorectal cancer (crc) is the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide. the incidence of crc is known to be high in developed countries and increases with socioeconomic development. well-known risk factors include aging, alcohol consumption, smoking, and obesity. in addition to family history, lifestyle changes in diet, occupation, or physical activity may also emerge as risk factors for crc. previous research findings have shown a significant association between reduced physical activity and an increased risk of crc. with improved patient survival rates, functional outcomes such as fecal incontinence, urinary, and sexual dysfunction are becoming increasingly important, as they are known to significantly impact quality of life (qol). reviewing the functional outcomes of rectal cancer surgeries, it is observed that even years after surgery, one-third of patients suffer from fecal incontinence. in contrast, studies on the functional outcomes following colon cancer surgeries are rare and often involve relatively small study populations. previous studies have shown that physical activity in cancer survivors can have numerous beneficial health effects and is associated with a reduced risk of cancer recurrence and mortality in cases of colon and rectal cancer.

Eligibility criteria:
inclusion criteria: * adult (18-80 years) patients with a diagnosis of colorectal or anal carcinoma exclusion criteria: * neuromuscular diseases * severe congenital musculoskeletal and other disorders, * severe psychiatric illness, lack of cooperation, * undergone other surgical procedures within the past year.

Keywords: colorectal cancer anal cancer quality of life physical activity fecal incontinence
ct assessment of bmi in endometrial cancer patients

Conditions: Endometrial Cancer

Summary: this study is a retrospective study to investigate the association between body fat distribution and sarcopenia on ct-scan and oncological outcomes in endometrial cancer patients


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of endometrial cancer * age: 18 years or older * abdominal ct-scan as part of pre-operative or post-operative staging work-up (\<1 month after surgery) exclusion criteria: * women with concurrent cancer * women with unknown body mass index

Keywords: endometrial cancer ct-scan fat distribution obesity sarcopenia
resolute japan - the clinical evaluation of the mdt-4107 drug-eluting coronary stent

Conditions: Arterial Occlusive Diseases; Myocardial Ischemia; Cardiovascular Diseases; Coronary Artery Disease

Summary: the objective of the study is to verify the safety and efficacy of the mdt-4107 drug-eluting coronary stent for the treatment of de novo lesions in native coronary arteries.


Eligibility criteria:
inclusion criteria: * acceptable candidate for percutaneous coronary intervention (pci),stenting, and emergency coronary artery bypass graft surgery * clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia and/or positive functional study * informed consent * patient agrees to comply with specified follow-up evaluations at same investigational site * single target lesion or two target lesions located in separate coronary arteries * de novo lesion(s) in native coronary artery(ies) * target lesion(s) ≤ 27 mm in length * target vessel(s) have reference vessel diameter 2.5 mm to 3.5 mm exclusion criteria: * within 7 days of implant platelet count \ 700,000 cells/mm³; white blood cell (wbc) count \ 2.5 mg/dl * acute myocadial infarction (mi) within 72 hrs of the index procedure (q wave myocardial infarction(qwmi) or any elevation of creatinine kinase mycocardial-band isoemzyme (ck-mb) \> lab upper limit of normal) * previous pci of target vessel(s) within 9 months prior to the procedure * planned pci of any vessel within 30 days post-index procedure and/or planned pci of target vessel(s) within 12 months post-index procedure * history of stroke or transient ischemic attack (tia) within prior 6 months * participating in investigational drug/device study that has not completed primary endpoint or interferes with study endpoints * inability to comply with required trial antiplatelet regimen * previous stent in target vessel unless it has been at least 9 months since stent placed and target lesion(s) is/are at least 15 mm from previous stent * target vessel(s) has/have other lesions w/ \> 40% diameter stenosis * unprotected left main coronary artery disease

Keywords: target vessel revascularization (tvr) myocardial infarction (mi) target vessel failure (tvf) target lesion revascularization (tlr) target lesion failure (tlf) stent thrombosis restenotic lesion percutaneous coronary intervention (pci)
99mtc-mirc213 spect/ct for the detection of her2-positive breast cancer

Conditions: Breast Cancer

Summary: this is an open-label single photon emission tomography/computed tomography (spect/ct) study to investigate the imaging performance of 99mtc-mirc213 in breast cancer patients. a single dose of 11.1-14.8mega-becquerel (mbq) per kilogram body weight 99mtc-mirc213 will be injected intravenously. visual and semiquantitative method will be used to assess the spect/ct images.

99mtc-mirc213 is an nano affibody probe targeting her2. the investigators will determine the use of 99mtc-mirc213 spect/ct in the detection of her2- positive breast cancer, and to compare its diagnostic value with routine immunohistochemistry (ihc) pathological staining. her2 imaging, specifically to her2 receptor expressed on malignant breast cancer cell surface, might help for targeted therapy with monoclonal antibody such as trastuzumab in breast cancer, and may improve the treatment strategy of breast cancer. the investigator will determine the use of 99mtc-mirc213 spect/ct in stratifying breast cancer.

Eligibility criteria:
inclusion criteria: * patients in suspicion of breast cancer by mammography or ultrasonography,and being able to provide basic information and sign the written informed consent form exclusion criteria: * the exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study, and undergoing any preceding local or systemic therapies that might interfere with her2 binding.

Keywords: spect/ct her2
study by metagenomics and culturomicsapproaches of bacterial and viral flora of diabetic foot infection

Conditions: Diabetic Foot Infection

Summary: this work also highlights the presence of an unknown virus double-stranded dna. in this project we propose 1) incorporating a bank of 150 samples from patients with diabetic foot infection in grades 2-4; 2) to study the microbial flora of a selection of 50 diabetic feet previously untreated with antibiotics for bacterial metagenomics, viral metagenomics and a minimum of 10 per culturomique; 3) to evaluate the use of targeted quantitative pcr on the most frequent new species frequency in the disease and incidentally get a sense of their role in the evolution and prognosis of the disease, including failures of and targeted antibiotic therapy on all 150 samples.

patients will be included by the infectious and tropical diseases and diabetes services the nîmes teaching hospital which have a large active file and proven expertise internationally in this pathology. the usual agents of infection will be searched by standard bacteriological techniques as part of the microbiological documentation of such cases and will be performed by the microbiology laboratory of chu nîmes which will freeze the rest of the sample to -80 ° c the will send it to the marseille microbiology federation for realization of metagenomics-culturomics

Eligibility criteria:
inclusion criteria: * patients were taken care by the services(departments) of diabetology or infectious diseases of the chu(teaching hospital) of nîmes, were hospitalized or were seen in consultation and presenting a wound chronicle of the foot and/or the ankle of rank 2 - 4 (classification of the iwgdf) \[iwgdf, lipsky clin infect dis on 2004\], inaugural or récidivante. exclusion criteria: * the patient participates in another study * the patient is in period of exclusion determined by a previous study * the patient is under protection(saving) of justice, under guardianship or under guardianship * the patient refuses to sign the consent * it turns out impossible to give about the lit(enlightened) information * the patient is pregnant, parturiente, or she breast-feeds * the patients having no wound * the patients diabetics having a wound chronicles of rank 1 (classification of the iwgdf) \[iwgdf, lipsky clin infect dis on 2004\]
study describing the coverage, cares and the fertility of patients of less than 45 years with a borderline ovarian tumor

Conditions: Borderline Ovarian Tumors

Summary: retrospective and prospective multi-center study indication: fertility-sparing surgery for patients with borderline ovarian tumor and fertility objectives: * description of the characteristics of the patients of less than 45 years having a fertility-sparing surgery for borderline ovarian tumors, the modalities of care and their fertility. * validation of a nomogram as an information medium to the patients concerned on their chance of alive birth according to their personal characteristics origin and nature of the specific data: * extraction from the database " tumeurs malignes rares de l'ovaire " (tmro) * collection of retrospective further informations in the participating centers * data collection from the patients (questionnaires) the data will be identified by the tmro number allocated to every participant of the tmro study . data traffic : tmro database extraction for the patients with bot and corresponding to the inclusion criteria, supplied by arcagy-gineco. the database will be managed by the coordination team in an anonymous way by means of the patient identifiers of the tmro base. enrichment of the base by the anonymous questionnaires filled by the patients and the complementary data transmissions of the centers on anonymised files.


Eligibility criteria:
inclusion criteria: * women with history of borderline ovarian tumor (bot). * women who have had first a fertility-sparing surgery. * women old enough to procreate (= 45 years) during their first surgery. * women having agreed to participate in the previous study "observatoire sur les tumeurs malignes rares de l'ovaire" (tmro). * women who have not expressed their opposition to the research. exclusion criteria: * the patients who are not corresponding to the selection criteria are straightaway excluded from the retrospective database selected for the study (tmro).

Keywords: borderline ovarian tumor (bot) fertility-sparing surgery gynecology oncology
the effect of vitamin d on bone accretion and turn-over in young girls

Conditions: Vitamin D Deficiency

Summary: objectives to evaluate the effect of increased vitamin d intake on vitamin d status, bone mass and bone turnover in young girls aged 12-13. more specifically the effects on the following parameters will be assessed: * vitamin d metabolites. * parathyroid hormone. * bone turnover. * bone mineral accretion. * serum calcium and phosphate. * renal handling of calcium and phosphate.

this work package will consist of a randomised double blind one-year vitamin d supplementation study. primary effect parameter is change in bone mineral content and therefore study duration will be one year. a total of 225 subjects, 75 in each of the three groups: one control and two intervention groups, will be included two dosages of supplementation will be used: 5 µg per day and 10 µg per day.

Eligibility criteria:
inclusion criteria: * girls born in denmark with danish citizenship aged 10.0-11.0 years living in the municipals of copenhagen and frederiksberg exclusion criteria: * any chronical disease with influence on bone mass or turnover * intake of drugs with influence on bone mass or turnover * intake of calcium or vitamin d other than the intervention

Keywords: vitamin d adolescent girls bone accretion bone turn over vitamin d status vitamin d insufficiency in young girls
bioequivalence between two new oral nicotine replacement therapy products and nicorette® microtab

Conditions: Tobacco Dependence

Summary: the purpose of this study is to assess the bioequivalence between two new oral nicotine replacement therapy products and nicorette® microtab.

the trial has a single-dose, randomized, crossover design and includes 84 subjects. the investigational products will be given as single doses at separate treatment visits. periods without nicotine replacement therapy (nrt), lasting for at least 36 hours, will separate treatment visits. at each treatment visit, blood for pharmacokinetic analyses will be sampled immediately before, and at 5, 10, 15, 20, 30, and 45 minutes, as well as at 1, 1.25, 1.5, 2, 3, 4, 6, 8, and 10 hours after start of product administration. the time until complete tablet dissolution will be recorded. subjects will also be monitored to capture any adverse events that may occur. treatment labels will be concealed from subjects and study personnel.

Eligibility criteria:
inclusion criteria: * healthy subjects, smoking at least 10 cigarettes daily during at least one year preceding inclusion and bmi between 17.5 and 30.0 kg/m2. * female participants of child-bearing potential are required to use a medically acceptable means of birth control. * a personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study. exclusion criteria: * pregnancy, lactation or intended pregnancy. * treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.

Keywords: smoking cessation nicotine